Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gedatolisib + trastuzumab
- Development stage
- Unknown
- Lead developer
- Celcuity
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Gedatolisib + trastuzumab is a combination therapy that targets both the PI3K/mTOR signaling pathway and HER2 receptor in cancer cells. Gedatolisib is a dual PI3K/mTOR inhibitor that blocks the mTOR/PIK3 signaling pathway involved in tumor growth and proliferation. Trastuzumab is a monoclonal antibody that binds to the HER2/neu receptor, reducing HER2 expression and inhibiting angiogenesis that supports tumor growth. This combination has shown particular promise in patients with HER2-positive metastatic breast cancer with PIK3CA aberrations who have progressed after multiple lines of therapy.
02
Targets
mTOR (Mammalian target of rapamycin kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on gedatolisib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gedatolisib + trastuzumab.